This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: JNJ & SNY's Coronavirus Product Development, Other Updates
by Kinjel Shah
J&J (JNJ) to begin human clinical studies on coronavirus vaccine candidate in September. Sanofi (SNY) begins outside U.S. study on Kevzara for severe COVID-19 infection.
Coronavirus Drug & Vaccine: 4 Companies Leading From the Front
by Nilanjan Banerjee
The present scenario has brightened up prospects for companies working on potential drugs and vaccines to combat the pandemic.
Sanofi to Withdraw Zantac After FDA Warns of Carcinogens
by Zacks Equity Research
The FDA requests drugmakers to withdraw all ranitidine medications, which includes Sanofi's (SNY) popular heartburn drug Zantac, due to possible increase in risk of cancer.
Coronavirus Vaccine Race Intensifies: 3 Stocks in Focus
by Ekta Bagri
Given the urgent need for preventing the spread of COVID-19 in future, let's take a look at the companies developing vaccines for the same.
Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development
by Sweta Jaiswal, FRM
The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
Gilead Expands Access to Experimental Coronavirus Treatment
by Zacks Equity Research
Gilead (GILD) looks to expand access programs to accelerate access to remdesivir for COVID-19 patients.
J&J Plans to Initiate Coronavirus Vaccine Study in September
by Zacks Equity Research
J&J (JNJ) announces its plan to start an early-stage clinical study on its selected vaccine candidate in September. The company also expands agreement with BARDA to accelerate vaccine development.
Sanofi (SNY) Catches Eye: Stock Jumps 5.3%
by Zacks Equity Research
Sanofi (SNY) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Sanofi Begins Kevzara Study for Severe Coronavirus Infection
by Zacks Equity Research
Sanofi (SNY) begins treatment in a second phase II/III study evaluating its rheumatoid arthritis drug Kevzara to treat patients with severe COVID-19 outside the United States.
Translate Bio, Sanofi to Jointly Develop Coronavirus Vaccine
by Zacks Equity Research
Translate Bio (TBIO) gains on collaboration with Sanofi for a mRNA vaccine development for COVID-19.
Gilead Asks FDA to Withdraw Orphan Drug Tag for Remdesivir
by Zacks Equity Research
Gilead (GILD) asks the FDA to revoke the Orphan Drug designation granted to its experimental drug, remdesivir, for the treatment of COVID-19.
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals
Novavax Rallies as Influenza Vaccine Meets All Goals in Study
by Zacks Equity Research
Novavax's (NVAX) NanoFlu, the influenza vaccine candidate for adults aged 65 years and older, meets all the primary and secondary endpoints in late-stage study. Shares rise.
Top 5 Drug Stocks To Stop The Coronavirus Pandemic
by Daniel Laboe
It is only a matter of time before this virus anxiety is a thing of the past.
Pfizer's Eczema Drug Eucrisa Gets FDA Approval for Infants
by Zacks Equity Research
Pfizer (PFE) gets FDA approval for label expansion of Eucrisa to include children aged three months to two years with mild-to-moderate atopic dermatitis or eczema.
Lilly Halts Enrollment, Biotechs Focus to Find Coronavirus Cure
by Kinjel Shah
Supply-chain disruptions due to coronavirus outbreak may hurt biotech companies' first-quarter earnings. However, those making treatments/vaccines may make huge profits if their products get approval.
The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck
Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates
by Kinjel Shah
Pfizer (PFE) is set to jointly develop BioNTech's potential coronavirus vaccine. Regeneron/Sanofi (SNY) and Roche will study their RA drugs, Kevzara & Actemra, respectively to treat severe COVID-19 infection.
Mylan, Teva in Focus As Chloroquine Being Tested for Coronavirus
by Ekta Bagri
Malaria drug, chloroquine, is being tested for the treatment of patients infected with COVID-19. Generic makers, Mylan and Teva ramp up efforts to contribute to the same.
The Zacks Analyst Blog Highlights: UnitedHealth, Sanofi, United Parcel Service, Caterpillar and Activision Blizzard
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth, Sanofi, United Parcel Service, Caterpillar and Activision Blizzard
Pfizer's Eczema Drug & Pneumococcal Vaccine Succeed in Study
by Zacks Equity Research
Pfizer's (PFE) atopic dermatitis (eczema) candidate, abrocitinib, and pneumococcal conjugate vaccine candidate meet primary endpoints in their respective late-stage studies.
J&J Files NDA for Multiple Sclerosis Drug Ponesimod in U.S.
by Zacks Equity Research
Johnson & Johnson's (JNJ) ponesimod's regulatory application in U.S is based on data from the head-to-head OPTIMUM phase III study, comparing it to Sanofi's MS drug, Aubagio.
Roche to Evaluate Actemra for Severe COVID-19 Pneumonia
by Zacks Equity Research
Roche (RHHBY) works with the FDA to evaluate the safety and efficacy of rheumatoid arthritis drug, Actemra, in severe COVID-19.
Drugs or Vaccines: Which Will Be More Crucial Against Coronavirus?
by Ekta Bagri
Given the urgent need for curing infected COVID-19 patients, we take a look at companies developing drugs/treatments for the same.
The Zacks Analyst Blog Highlights: REGN, SNY, GILD and MRNA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: REGN, SNY, GILD and MRNA